Gi Insights

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Sidney Barritt, MD Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That’s why Dr. Peter Buch speaks with Dr. Sidney Barritt about top treatment strategies for nonalcoholic fatty liver disease in part one of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the Director of Hepatology at the UNC Liver Center at the University of North Carolina.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Marianna Arvanitakis, MD, PhD Consuming ultra-processed foods can pose many risks to your health that go beyond the GI system. Explore the risks associated with ultra-processed foods with Dr. Peter Buch and Dr. Marianna Arvanitakis, Associate Clinical Professor in the Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology from the HUB Erasme Hospital in Brussels, Belgium.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Claire Jansson-Knodell, MD When a person has a low IgA level, the tissue transglutaminase immunoglobulin A antibody is no longer a useful screening test for celiac disease. So how should we be assessing patients with an IgA deficiency? To discuss these new recommendations, Dr. Peter Buch is joined by Dr. Claire Jansson-Knodell, Gastroenterologist at the Cleveland Clinic’s Digestive Disease Institute.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD Metoclopramide is the only FDA-approved medication for the treatment of gastroparesis; however, it comes with a black box warning. To discuss the challenges in diagnosing and treating gastroparesis, Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine, Pharmacology, and Physiology at the Mayo Clinic in Rochester, Minnesota.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE Assessing eosinophilic esophagitis (EOE) patients’ sensitivity to specific foods is key to creating a personalized diet to help treat this disease. So what role does the six-food elimination diet have in EOE patients? Dive in with Dr. Peter Buch as he speaks with Dr. Brooks Cash, Chief of the Division of Gastroenterology, Hepatology, and Nutrition at the University of Texas Health Sciences Center at Houston.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alan Bonder, MD According to this clinician, the most important thing for primary biliary cholangitis (PBC) patients is the diagnosis, and anyone with abnormal liver tests should be sent an antimitochondrial antibody (AMA). Dive into this interview with host Dr. Peter Buch and Dr. Alan Bonder, Assistant Professor of Medicine and the Medical Director of Liver Transplantation at Beth Israel Medical Center in Boston.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kunal Jajoo, MD Clinicians should be assessing their patients immediately and trying to understand how quickly they need to provide endoscopy and endoscopic therapy. So in patients with a high risk for thromboembolism, how soon after GI bleeding may anticoagulation be considered? Take a deep dive with Dr. Peter Buch as he speaks with Dr. Kunal Jajoo, Assistant Professor of Medicine at the Brigham and Women’s Hospital of Harvard Medical School.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alan Bonder, MD Patients with underlying autoimmune diseases could be at a higher risk of developing autoimmune hepatitis (AIH). So what challenges might occur when diagnosing patients with AIH? Learn more with Dr. Peter Buch as he discusses this with Dr. Alan Bonder, Director of Liver Transplantation at Beth Israel Deaconess Hospital and an Assistant Professor of Medicine at Harvard Medical School.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Neil Sengupta, MD Lower GI bleeding is one of the most common reasons that patients are hospitalized due to a digestive disorder in the U.S.; however, there is little data available to help clinicians manage this condition in their patients. So how can we provide better care for these patients? Tune in with Dr. Peter Buch as he speaks with Dr. Neil Sengupta, Associate Professor of Medicine at the University of Chicago.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Robert Wong, MD There may be benefit in testing all hepatitis B patients for hepatitis D, such as reducing the risk of disease progression and liver disease complications. So when should we be concerned about potential hepatitis D infection in our patients? Join Dr. Peter Buch as he discusses this with Dr. Robert Wong, Clinical Associate Professor at Stanford University.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Eamonn Quigley, MD A new treatment option may help relieve chronic constipation in patients who might not respond well to traditional therapies. To learn more about a novel FDA-approved vibrating capsule, join Dr. Peter Buch as he speaks with Dr. Eamonn Quigley, the David M. Underwood Chair of Medicine in Digestive Disorders and a Professor of Medicine at Houston Methodist.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Amit Singal, MD, MS Hepatocellular carcinoma (HCC) is the most common type of liver cancer and most often occurs in people with chronic liver disease. So should we be utilizing modalities other than standard ultrasound for routine early detection of HCC in cirrhotic patients? Listen to this discussion led by Dr. Peter Buch as he speaks with Dr. Amit Singal, Professor of Medicine and the Chief of Hepatology at the University of Texas Southwestern Medical Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Joel Rubenstein, M.D., M.Sc. Gastroesophageal reflux disease (GERD) is an important risk factor for Barrett’s esophagus and esophageal adenocarcinoma (EAC), but there are other important risk factors, such as gender and race. So is it time to look at alternative approaches to increase appropriate screenings? Join Dr. Peter Buch as he is joined by Dr. Joel Rubenstein, Research Scientist at the Kettles VA in Ann Arbor, Michigan and a Professor of Internal Medicine in the Department of Gastroenterology and Hepatology at the University of Michigan School of Medicine.

Host: Neilanjan Nandi, MD Guest: Monika Fischer, MD Clostridioides difficile, or C. difficile for short, is a bacteria that continues to plague our patients. What are the latest treatment updates that you need to be aware of? Dr. Neil Nandi is joined by Dr. Monika Fischer from Indiana University to dive into treatment options and discuss the latest updates.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brooks D. Cash, MD, AGAF, FACG, FASGE Acute colonic pseudo-obstruction, also known as Ogilvie’s syndrome, is a rare form of colonic dilatation that can be serious and life-threatening. To learn more about this disorder, Dr. Peter Buch and Dr. Brooks Cash take a look at risk factors, testing strategies, and treatment options for Ogilvie’s syndrome.

Host: Neilanjan Nandi, MD Guest: Megan E. Riehl, PsyD In an age where there’s an app for everything, are smartphone apps and other technology-enable solutions revolutionizing mental health treatment in patients with GI challenges? Dr. Neil Nandi speaks with Dr. Megan Riehl from the University of Michigan to explore the capabilities of these technologies and their role in treatment.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Maurizio Bonacini, MD Patients with cirrhosis of the liver are typically more susceptible to portal vein thrombosis (PVT). So how can we provide the best care to our PVT patients? To find out, Dr. Peter Buch is joined by Dr. Maurizio Bonacini, CEO of Mission Gastroenterology and Hepatology and Associate Clinical Professor of Medicine at the University of California, San Francisco.

Host: Neilanjan Nandi, MD Guest: Gursimran Kochhar, MD What do the guideline updates recommend for the endoscopic treatment of Crohn’s disease strictures? Dr. Neil Nandi speaks with one of the guideline authors, Dr. Gursimran Kochhar from the Allegheny Health Network in Pittsburgh, Pennsylvania, to better understand how to manage these strictures.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Koji Hashimoto, MD, PhD What facts should we keep in mind when considering liver transplantation? And how do we determine which of our patients are the right candidates? Dr. Peter Buch explores important considerations for liver transplantation with Dr. Koji Hashimoto, the Director of Liver Transplantation at the Cleveland Clinic.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: John Pandolfino, MD, MSCI From bird beaking to functional lumen imaging probes (FLIP), what do we need to know about the presentation and treatment of achalasia? Dr. Peter Buch speaks with Dr. John Pandolfino from the Feinberg School of Medicine at Northwestern University about the various treatment options available for achalasia.